quinazolines has been researched along with Lymphangiomyomatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiou, TT; Gallacchi, D; Kwiatkowski, DJ; Lee, PS; Li, C; Malinowska, IA; Pereira, AM; Reynolds, SB; Robinson, L; Sun, Y; Yu, JJ; Zhang, EY | 1 |
| Keane, MP; Kelly, E; McDonnell, TJ; Mhurchu, EN; Sukor, S; Tryfonopoulos, D | 1 |
2 other study(ies) available for quinazolines and Lymphangiomyomatosis
| Article | Year |
|---|---|
Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Topics: Animals; Antineoplastic Agents; Cell Line; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Humans; Isoquinolines; Lung Neoplasms; Lymphangioleiomyomatosis; Mice, Inbred C57BL; Mice, SCID; Molecular Targeted Therapy; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Sirolimus; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Chemotherapy-associated recurrent pneumothoraces in lymphangioleiomyomatosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Lung Neoplasms; Lymphangioleiomyomatosis; Middle Aged; Neoplasms, Second Primary; Oxygen Inhalation Therapy; Pneumothorax; Quinazolines; Trastuzumab | 2010 |